https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-20 / JCI Insight 2017 Apr;2(8)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-20 / JCI Insight 2017 Apr;2(8)2017-04-20 00:00:002019-02-15 08:49:48Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-18 / Oncotarget 2017 Apr;8(16):27252-27262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-18 / Oncotarget 2017 Apr;8(16):27252-272622017-04-18 00:00:002019-02-15 08:39:10Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-1909
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-15 / Clin. Cancer Res. 2017 04;23(8):1898-19092017-04-15 00:00:002019-02-15 08:47:32Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-14 / Cancer 2017 Aug;123(16):3061-3072
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-14 / Cancer 2017 Aug;123(16):3061-30722017-04-14 00:00:002019-02-15 08:32:48Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-04-07 / J Hematol Oncol 2017 04;10(1):82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-04-07 / J Hematol Oncol 2017 04;10(1):822017-04-07 00:00:002019-02-15 08:52:39Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-22 / J Transl Med 2017 03;15(1):64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-22 / J Transl Med 2017 03;15(1):642017-03-22 00:00:002019-02-15 08:47:53Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-4742017-03-05 00:00:002019-02-15 08:47:44Immune and viral therapies for malignant primary brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-3032017-03-02 00:00:002019-02-15 08:51:58A comprehensive review of immunotherapies in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-01 / Immunotherapy 2017 03;9(4):319-329
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-01 / Immunotherapy 2017 03;9(4):319-3292017-03-01 00:00:002019-02-15 08:48:14Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)2017-02-23 11:47:542021-05-19 14:29:04Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trial.
